Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is ...

Why do some patients with precursors to bone marrow cancer never develop the disease? Researchers from the Department of Forensic Medicine at Aarhus University have discovered that some cells enter a ...

M ultiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

Genetic changes in plasma cells may change how these cells function, causing them to multiply rapidly and produce abnormal proteins called monoclonal antibodies (M-proteins)—which don't ...

Abstract. B-cell maturation antigen (BCMA) is the target of several investigational and approved drugs for multiple myeloma. BCMA expressed on plasma cells (PC) and multiple myeloma cells is cleaved ...

Triple monoclonal protein-related kidney lesions are very rare and are usually associated with multiple myeloma. Light chain cast nephropathy (LCCN) is a myeloma-defining event but his light chain (LC ...

To explore whether C3d could induce CMI against malignant plasma cells and/or premalignant precursor cells and hence evoke immune surveillance, we tested whether administration of a recombinant C3d ...

Although previous literature has suggested a causal relationship between MGUS or other plasma cell dyscrasias and low bone density, 3,4 it remains unclear whether a causal relationship indeed exists ...

Conditions of monoclonal gammopathies range from benign to malignant diseases, such as multiple myeloma, due to an overproduction of abnormal plasma cells. For analysis, the two-step extraction ...